AG3340
AG3340
AG3340 (pronunciation: A-G-Three-Three-Four-Zero), also known as Prinomastat, is a potent, synthetic, broad-spectrum matrix metalloproteinase (MMP) inhibitor. It was developed by Agouron Pharmaceuticals and is primarily used in the research of various cancer types.
Etymology
The term AG3340 is derived from the name of the pharmaceutical company, Agouron, that developed it, and the specific number 3340 is likely an internal designation used during its development.
Function
AG3340 functions by inhibiting the activity of MMPs, a group of enzymes that play a crucial role in the degradation of the extracellular matrix (ECM). By inhibiting these enzymes, AG3340 can prevent the breakdown of the ECM, which is a key process in the spread of cancer cells.
Clinical Trials
AG3340 has been tested in clinical trials for its potential use in treating various types of cancer, including lung cancer, prostate cancer, and breast cancer. However, the results have been mixed, and further research is needed to determine its efficacy and safety.
Related Terms
External links
- Medical encyclopedia article on AG3340
- Wikipedia's article - AG3340
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski